ATE198152T1 - Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe - Google Patents

Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe

Info

Publication number
ATE198152T1
ATE198152T1 AT95932202T AT95932202T ATE198152T1 AT E198152 T1 ATE198152 T1 AT E198152T1 AT 95932202 T AT95932202 T AT 95932202T AT 95932202 T AT95932202 T AT 95932202T AT E198152 T1 ATE198152 T1 AT E198152T1
Authority
AT
Austria
Prior art keywords
active ingredients
pct
delayed release
medicinal preparation
oral medicinal
Prior art date
Application number
AT95932202T
Other languages
English (en)
Inventor
Shigeyuki Takada
Yasushi Nakagawa
Susumu Iwasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE198152T1 publication Critical patent/ATE198152T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95932202T 1994-09-30 1995-09-21 Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe ATE198152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23794894 1994-09-30
PCT/JP1995/001905 WO1996010397A1 (en) 1994-09-30 1995-09-21 Oral sustained-release preparation

Publications (1)

Publication Number Publication Date
ATE198152T1 true ATE198152T1 (de) 2001-01-15

Family

ID=17022843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932202T ATE198152T1 (de) 1994-09-30 1995-09-21 Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe

Country Status (7)

Country Link
US (1) US6113941A (de)
EP (1) EP0800385B1 (de)
AT (1) ATE198152T1 (de)
AU (1) AU3533395A (de)
CA (1) CA2197327A1 (de)
DE (1) DE69519685T2 (de)
WO (1) WO1996010397A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
EP0839525B1 (de) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter Freisetzung
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
DK1075276T3 (da) * 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20040091528A1 (en) * 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
JP4723864B2 (ja) * 2002-12-19 2011-07-13 日本曹達株式会社 Ｏｉｌ／Ｗａｔｅｒ液中乾燥法による農薬マイクロカプセル製剤及びその製造方法
JP2004331750A (ja) * 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1688169A4 (de) * 2003-11-28 2008-10-01 Mitsubishi Chem Corp Verfahren zur herstellung von feinen teilchen einer organischen verbindung
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20060147515A1 (en) * 2004-12-02 2006-07-06 Zhongzhou Liu Bioactive dispersible formulation
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
EP2009991A1 (de) * 2006-04-10 2009-01-07 Janssen Pharmaceutica N.V. Kombinationen von 4-brom-2-(4-chlorphenyl)-5-(trifluormethyl)-1h-pyrrol-3-carbonsäurenitril und bioziden verbindungen
US8496968B2 (en) * 2007-11-07 2013-07-30 Kaneka Corporation Method for production of microcapsules using solid fat
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US9511341B2 (en) * 2013-08-30 2016-12-06 Sunny Pharmtech Inc. Method for preparing acetazolamide sodium powder
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
KR102041821B1 (ko) * 2016-01-13 2019-11-08 주식회사 엘지화학 마이크로 입자 및 화장료 조성물
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059571T3 (es) * 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
EP0357061B1 (de) * 1988-09-01 1994-06-08 Takeda Chemical Industries, Ltd. Angiogenese hemmendes Mittel
ATE150750T1 (de) * 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol-derivate
DE69004598T2 (de) * 1989-03-06 1994-03-24 Takeda Chemical Industries Ltd 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung.
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
AU7558991A (en) * 1990-03-15 1991-10-10 United States Of America, As Represented By The Secretary Of The Army, The Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
EP0535937B2 (de) * 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法

Also Published As

Publication number Publication date
US6113941A (en) 2000-09-05
EP0800385A1 (de) 1997-10-15
DE69519685D1 (de) 2001-01-25
WO1996010397A1 (en) 1996-04-11
CA2197327A1 (en) 1996-04-11
AU3533395A (en) 1996-04-26
DE69519685T2 (de) 2001-08-02
EP0800385B1 (de) 2000-12-20

Similar Documents

Publication Publication Date Title
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
DE69100991D1 (de) Pharmazeutische formulierungen.
DE69521688D1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
ATE261301T1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende arzneimittel
AU1227899A (en) Osmotic medicament releasing system
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
YU47899B (sh) Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
ES2130278T3 (es) Preparacion de morfina de liberacion controlada.
AU6136199A (en) Dosage form comprising therapeutic formulation
ATE116843T1 (de) Lösungsmittelfreie, oral zu verabreichende pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung und verfahren zu deren herstellung.
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
EE03954B1 (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvormi valmistamise meetod
ATE285252T1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GEP20043377B (en) Pharmaceutical Complex
NZ502807A (en) Preparation of solid oral dosage forms of alendronic acid (4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid)
GR3024854T3 (en) Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances.
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
FR2803521B1 (fr) Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
RU97109989A (ru) Способ лечения вагинозов и вагинитов у беременных

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties